tanya dorff, md, shares thoughts of the optimal sequence of atezolizumab and sip-t in mcrpc
Published 4 years ago • 41 plays • Length 0:23Download video MP4
Download video MP3
Similar videos
-
0:37
tanya dorff, md, elaborates on data investigating atezolizumab and cabozantinib in prostate cancer
-
2:49
sequencing atezolizumab and sipuleucel-t for castration resistant prostate cancer
-
2:11
role of sipulucel t caccines and immunotherapy in prostate cancer
-
30:09
overview: advanced prostate cancer treatments | tanya dorff, md | 2021 pcri conference
-
1:24
dr. dorff discusses the use of parp inhibitors in prostate cancer
-
3:42
common tamoxifen side effects
-
14:39
new fda approved parp inhibitor: talzenna (talazoparib) & xtandi | #markscholzmd #alexscholz #pcri
-
31:24
optimizing androgen deprivation therapy (adt) in advanced prostate cancer
-
3:14
2021 asco direct san francisco | prostate cancer summary | dr. tanya dorff
-
2:25
an expert overview of emerging prostate cancer treatments
-
13:00
what prostate cancer patients need to know about treatment during the covid-19 pandemic
-
4:36
expert report on latest data in the management of metastatic prostate cancer from asco 2022
-
5:18
prostate cancer updates with dr. tanya dorff and dr. sumanta pal—practiceupdate's esmo 2016 coverage
-
2:00
why should people with prostate cancer share emotional issues with their team?
-
1:01:31
20-02. dr tanya dorff "prostate cancer immunotherapy update" feb 27, 2020
-
30:08
the quality of life cost of living with advanced stage prostate cancer
-
2:30
strategies for treating advanced prostate cancer symptoms
-
0:33
finding the fit for immunotherapy in prostate cancer
-
6:54
talapro-2: toxicities and treatment duration
-
1:33
recommendations, benefits and risks of prostate cancer screening – dr. matthew tollefson
-
1:40
advances in prostate cancer imaging
-
4:51
advances in prostate cancer at esmo 2017